Topic
Topic
UCHealth reports a 36-year-old mother of three, previously dying of melanoma, treated successfully with tumor-infiltrating lymphocyte (TIL) therapy — her own immune cells, expanded and reinfused.
Dr. Ankit Mangla asks whether chemotherapy can bridge relapsed-refractory melanoma patients to TIL therapy, spotlighting the lymp…
Vanderbilt Health News has issued a one-line notice confirming a melanoma patient received tumor-infiltrating lymphocyte therapy,…
Obsidian Therapeutics will present updated Phase 1/2 data on amsoki-cel (OBX-115), its engineered TIL therapy, in advanced melano…
Iovance Biotherapeutics shares surged after Barron's reported strong demand for its melanoma drug is driving company growth, sign…
Iovance Biotherapeutics shares surged as strong demand for its melanoma drug drove company growth, signaling the therapy's uptake…
